We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Analysts Expect Surge in Parkinson's Disease Treatment Market

By LabMedica International staff writers
Posted on 12 Jul 2015
Print article
The market for drugs to treat Parkinson's disease is expected to grow dramatically over the next several years, driven primarily by an aging population and increasing disease prevalence.

Three new drugs are expected to lead the surge of newly approved drugs and drug candidates. These include Rytary, manufactured by Impax (Hayward, CA, USA), which was approved by the US Food and Drug Administration (FDA) in January 2015; safinamide (Xadago) from Newron Pharmaceuticals (Milan, Italy), which was approved in Europe in February 2015 and accepted for a New Drug Application by the FDA in March 2015; and CVT-301, which is being developed by Acorda (Ardsley, NY, USA).

Rytary is a combination of carbidopa (an aromatic amino acid decarboxylation inhibitor) and levodopa (an aromatic amino acid) indicated for the treatment of Parkinson’s disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication.

Safinamide is a reversible and selective monoamine oxidase B inhibitor, reducing degradation of dopamine, and a glutamate release inhibitor. It also seems to inhibit dopamine reuptake. Additionally, safinamide blocks sodium and calcium channels.

CVT-301 is a self-administered, inhaled formulation of levodopa (L-dopa) in development for treatment of OFF episodes in Parkinson’s disease, and is being studied to provide rapid, reliable delivery of a precise dose of L-dopa through the lungs to return people with Parkinson’s to an ON state. OFF episodes, which increase in frequency and severity during the course of the disease, are defined by periods of time when background L-dopa therapy does not adequately control Parkinson’s symptoms.

The market analysis firm GlobalData (London, United Kingdom) estimated that the Parkinson’s disease treatment market value across the eight major countries of the USA, France, Germany, Italy, Spain, the United Kingdom, Japan, and Brazil will reach 4.7 billion USD by 2022.

GlobalData further predicted that global sales for safinamide and Rytary will reach 409.6 million USD and 202.2 million USD, respectively, by 2022. They also suggested that CVT-301 would garner strong sales of 458.6 million USD in 2022.

Related Links:

Impax
Newron Pharmaceuticals
Acorda


New
Gold Member
Pneumocystis Jirovecii Detection Kit
Pneumocystis Jirovecii Real Time RT-PCR Kit
Automated Blood Typing System
IH-500 NEXT
New
Anti-Secukinumab ELISA
LISA-TRACKER anti-Secukinumab
New
Free Human Prostate-Specific Antigen CLIA
LIAISON fPSA

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.